Biomarkers for Early Detection of Hematopoietic Malignancies (R21) | Apply Online

Opportunity Summary:

The Biomarkers for Early Detection of Hematopoietic Malignancies (R21) opportunity (Funding Opportunity Number PA-09-198) is a discretionary National Institutes of Health grant announcement led by the National Cancer Institute. Its main goal is to spur exploratory, early stage research that identifies, develops, and validates measurable biomarkers that can help detect blood and bone marrow cancers earlier, anticipate which cases may progress, and monitor for recurrence after treatment. A strong emphasis is placed on work that benefits high risk individuals, where earlier or more accurate detection could meaningfully change clinical decisions and outcomes. In addition to early detection and recurrence monitoring, the announcement also supports biomarker approaches that improve risk assessment for both primary hematopoietic malignancies and secondary malignancies (for example, cancers that arise after prior therapy or other exposures).

A key feature of the announcement is that it does not only seek new biomarkers in the abstract; it also explicitly encourages the development and refinement of the technologies and methods needed to detect those biomarkers quantitatively. In practical terms, this means applications can focus on creating or improving assays, platforms, analytical techniques, or other measurement approaches that make novel biomarker signals detectable, reliable, and usable in research or clinical-adjacent settings. The underlying idea is that better measurement tools and more rigorous validation strategies are often what turn promising biomarker leads into something that can be tested and eventually adopted more broadly.

The funding mechanism is the NIH Exploratory/Developmental Grant (R21), which is designed for innovative, higher risk projects that are still at a proof-of-concept stage. The scientific scope runs in parallel with a companion announcement that uses the R01 mechanism (PA-09-197), which typically supports more mature projects with a larger evidence base. This R21 version is therefore geared toward earlier development steps such as feasibility testing, initial validation, method development, and generating the data needed to justify larger scale studies later.

Financially, the opportunity lists an award ceiling of $200,000, and it notes that the final size and duration of individual awards can vary depending on what the proposed research requires. Rather than guaranteeing a fixed number of awards, NIH indicates that total dollars and award counts depend on the volume of submissions, their quality, the timeframes proposed, and the costs requested. There is no cost sharing or matching requirement, which lowers barriers for applicants that may not have non-federal funds to contribute.

Eligibility is broad and includes many organization types: public and state controlled institutions of higher education, private institutions of higher education, nonprofits with and without 501(c)(3) status (excluding higher education where specified), small businesses, other for-profit organizations, and state governments. The announcement also allows additional eligible applicants such as certain federal agencies, Hispanic-serving institutions, U.S. territories and possessions, regional organizations, and non-U.S. entities (foreign organizations), indicating an openness to a wide range of institutional settings and collaborative structures.

From an administrative standpoint, the opportunity was posted and created on June 1, 2009, with a closing date of September 7, 2012, and an archive date of October 8, 2012, meaning it is no longer open for new submissions under that specific posting. The activity categories align with health and education, and it is associated with CFDA program areas 93.393 (Cancer Cause and Prevention Research) and 93.394 (Cancer Detection and Diagnosis Research, reflecting its focus on both understanding cancer risk and improving detection. The full announcement was hosted through the NIH grants guide (link provided in the source), and NIH Office of Extramural Research support contacts were listed for technical access issues.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health

Next opportunity: Identifying Non coding RNA Targets for Cancer Early Detection and Prevention (R21)

Previous opportunity: Biomarkers for Early Detection of Hematopoietic Malignancies (R01)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PA 09 198

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PA 09 198) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PA 09 198", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.